Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004072 · ClinicalTrials.gov registry record · Phase 2

O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma

A Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by Case Comprehensive Cancer Center.

Completed
Registry status
Phase 2
Development phase
17
Enrollment target
3
Study locations

NCT00004072 is a Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 17 participants, below the 769-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00004072, a Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm, has completed, sponsored by Case Comprehensive Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
17 participants
Enrollment target
3
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining O6-benzylguanine with carmustine in treating patients who have previously untreated, refractory, or relapsing multiple myeloma.

Conditions Studied

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

  • DRUG O6-benzylguanine
  • DRUG carmustine

Study Locations (3)

Ohio

  • Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center - Cleveland
  • MetroHealth Medical Center - Cleveland

Illinois

  • University of Chicago Cancer Research Center - Chicago

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 1999-09
Est. Completion 2004-09
Phase Phase 2

Sponsor

Case Comprehensive Cancer Center

407 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00004072

The ClinicalTrials.gov registry entry for NCT00004072 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 769-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (98% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma and Plasma Cell Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which O6-benzylguanine is the first listed.

NCT00004072 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Illinois.

Frequently Asked Questions

What is clinical trial NCT00004072 about?

NCT00004072 is a clinical study titled "O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining O6-benzylguanine with carmustine in treating patients who h...

What is the current status of trial NCT00004072?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 1999-09. Estimated completion is 2004-09.

What conditions does trial NCT00004072 study?

This clinical trial studies the following conditions: Multiple Myeloma and Plasma Cell Neoplasm.

What interventions are being tested in trial NCT00004072?

The interventions under investigation include: O6-benzylguanine (DRUG), carmustine (DRUG).

Who is sponsoring clinical trial NCT00004072?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00004072 being conducted?

This trial has 3 study locations across Illinois, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma and Plasma Cell Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma and Plasma Cell Neoplasm

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.